Breaking News From Pharma & Bio Ingredients
SkyePharma Gets Australian OK for Solaraze
Posted on 2006-11-28 07:35:00
SkyePharma PLC today announces that Solaraze, its topical 3% gel (diclofenac sodium) treatment for actinic keratosis, has been approved for registration by the Australian Government Department of Health and Ageing Therapeutic Goods Administration (TGA).
Actinic keratosis is the most frequently occurring form of carcinoma 'in situ'1 and has approximately a 10% risk of developing into invasive squamous cell carcinoma2.
SkyePharma's marketing partner in Australia is Shire Pharmaceuticals plc, which hopes to launch Solaraze in early 2007 subject to discussions with distributors and approval of product information by the TGA.
SkyePharma will receive double digit royalty payments on net sales once marketed.
Subscribe via RSS
